🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Salvage Ultrahypofractionated Postoperative External Radiotherapy For Biochemical Recurrence

Recruitingn/aAges 18 Years - 90 YearsMaleUniversity of Milano Bicocca
NCT06941363 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Recently, the Radiation Oncology Department at Fondazione IRCCS San Gerardo dei Tintori has been renovated and has been equipped with cutting edge technologies to treat prostate cancer. Specifically, the now available technology can track organ motion in real time, thus allowing improved precision in radiation delivery, with increased protection of the surrounding organs at risk. These facilities have already enabled the kickoff of two prospective observational trials, the ABRUPT and the POPART, which are currently ongoing in the treatment of intact prostate and the biochemical recurrence, respectively. Taken together, these observations provide the basis for the prospective clinical study herein proposed. Patients enrolled in the study will undergo salvage single stereotactic RT to the prostate bed by means of image guided volumetric intensity-modulated arc technique (IGRT-VMAT) and sta

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Subjects of male sex ≥ 18 years of age. * Subjects have freely signed the pertinent informed consent before the beginning of the study * Adenocarcinoma of the prostate treated with radical prostatectomy (any type of radical prostatectomy is permitted including retropubic, perineal, laparoscopic or robotically assisted; there is no time limit for the date of radical prostatectomy) * Detectable post-prostatectomy PSA of ≥ 0.1 - \< 2.0 ng/mL either (1) persistently detectable post-operatively or (2) developing biochemical recurrence after prostatectomy (initially undetectable) * No evidence of N1 and/or M1 disease assessed by PSMA PET-CT within 90 days prior to registration * Negative Magnetic Resonance Imaging (MRI) of the pelvis in case of equivocal evidence of local relapse on PSMA PET-CT * Androgen deprivation therapy (ADT) allowed as per physician's discretion * ECOG performance status of 0-1 * Ability to complete the questionnaires Exclusion Criteria: * N1 and or M1 patients * Macroscopic local relapse at pelvic MRI. * Prior radiation of any kind to the prostate gland or pelvis * Prior brachytherapy * History of inflammatory colitis or other active severe comorbidities * Patients who are on immunosuppressant medication
💊

What it tests

  • SDRT
📍

Where

1 site
Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori (University of Milan Bicocca)
Monza, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy